Emerging information highlight the compound, a dual stimulant for GLP-1 and the second receptor, demonstrate promising potential in treating excess body fat and associated disease states. Early clinical trials suggest https://retatrutideresearchlab.co.uk/product/ozempic-025-mg-peptide/